OncoTherapy Science, Inc. (TYO:4564)
Japan flag Japan · Delayed Price · Currency is JPY
27.00
+1.00 (3.70%)
Jul 3, 2025, 3:30 PM JST

OncoTherapy Science Revenue

In the fiscal year ending March 31, 2025, OncoTherapy Science had annual revenue of 750.00M JPY with 22.95% growth. OncoTherapy Science had revenue of 187.00M in the quarter ending March 31, 2025, with 29.86% growth.

Revenue
750.00M
Revenue Growth
+22.95%
P/S Ratio
9.92
Revenue / Employee
15.96M
Employees
54
Market Cap
7.44B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 2025750.00M140.00M22.95%
Mar 31, 2024610.00M-524.00M-46.21%
Mar 31, 20231.13B-19.00M-1.65%
Mar 31, 20221.15B821.00M247.29%
Mar 31, 2021332.00M16.00M5.06%
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro
Mar 31, 2018 Pro Pro Pro
Mar 31, 2017 Pro Pro Pro
Mar 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Chugai Pharmaceutical 1,222.12B
Takeda Pharmaceutical Company 4,581.55B
Daiichi Sankyo Company 1,886.26B
HOYA Corporation 866.03B
Terumo 1,036.17B
Otsuka Holdings 2,393.18B
Astellas Pharma 1,912.32B
Shionogi & 438.27B
Revenue Rankings